Quick answer

Cannabis use disorder (CUD) has no FDA-approved medication. First-line treatment is talk therapy, mainly cognitive behavioral therapy (CBT) and motivational enhancement therapy (MET). Contingency management, which gives small rewards for negative drug tests, has the strongest controlled-trial support. Withdrawal symptoms start within 1 to 3 days of stopping, peak in the first week, and can last 2 to 3 weeks. About 1 in 10 adults who use cannabis develop CUD. The figure is about 1 in 6 for people who start in their teens.

Behavioral therapies with evidence

  • CBT: 6 to 12 sessions. Targets triggers, craving management, and relapse planning. Delivered alone or with MET.
  • MET and motivational interviewing: 2 to 4 sessions. Builds the person's own reason to cut down or stop. Works as a first step for people who are unsure.
  • Contingency management: vouchers or prizes for confirmed abstinence. Effect size is larger than other therapies in several trials. Uptake in the US is limited by funding rules.
  • Family-based therapy: multidimensional family therapy for adolescents. Targets family communication plus peer influence.
  • Community reinforcement approach: rebuilds daily routines and social contact that do not center on use.

Format varies: individual, group, in person, or telehealth. Session counts above come from trial protocols, not fixed rules.

Medication status

No drug has FDA approval for CUD. Several have been studied off-label with mixed results:

  • N-acetylcysteine (NAC): tested in adolescents. Trials show mixed results on cannabis use and craving.
  • Gabapentin: small trials suggest a drop in use and better sleep during withdrawal. Evidence is weak.
  • Dronabinol and nabilone: synthetic cannabinoids tested for withdrawal symptoms. Risk of misuse limits use.
  • Topiramate: some reduction in use in small trials. Side effects cause high dropout.

Off-label use needs a prescriber who reviews liver, kidney, and psychiatric history. Dosages in trials varied, so no standard regimen exists.

Withdrawal and early abstinence

DSM-5 cannabis withdrawal includes irritability, anger, insomnia, poor appetite, restlessness, anxiety, depressed mood, and craving. Symptoms are uncomfortable but rarely dangerous. Sleep problems often last longest. Practical steps: set a stop date, clear the home, plan for the first week, and treat insomnia with sleep hygiene before sedatives.

Digital and self-help options

Brief internet interventions and smartphone apps show small effects in trials. They suit mild cases or people who will not attend clinic visits. Effects are smaller than clinician-delivered CBT.

How to choose

  1. Count DSM-5 criteria. Two or more within 12 months means CUD. Six or more means severe.
  2. Match intensity to severity. Mild cases often start with brief MET. Moderate to severe cases warrant CBT plus contingency management.
  3. Screen for co-occurring depression, anxiety, ADHD, and alcohol use. Treating these changes CUD outcomes.
  4. Check coverage and cost. In the US, the SAMHSA National Helpline (1-800-662-4357) routes callers to sliding-scale programs.

Where CBD fits

No CBD product is approved to treat cannabis use disorder or cannabis withdrawal. Published trials on CBD for CUD are small and short, and results on use and craving are mixed. CBD does not replace therapy. People who use CBD alongside treatment should check the certificate of analysis for cannabinoid content and contaminants.